+357 96 030922
info@marketpublishers.com

Hemostasis Diagnostics Market Size, Share & Trends Analysis Report By Product (POC Testing Systems, Consumables), By Test (Prothrombin Time Test, D Dimer Test), By End Use, By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/H0E11B791F7EEN.html
Date: January 2025
Pages: 180
Price: US$ 5,950.00 (Single User License)
ID: H0E11B791F7EEN

Abstracts

This report can be delivered to the clients within 3 Business Days

Hemostasis Diagnostics Market Growth & Trends

The global hemostasis diagnostics market size is expected t%li%reach USD 1.49 billion by 2030, registering a CAGR of 4.5% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The market is likely t%li%show significant growth due t%li%various factors, such as the growing geriatric population across the globe, advancements in diagnostic technologies, increasing awareness of bleeding and clotting disorders, and the rising prevalence of chronic diseases.

One of the primary drivers of the market is the growing geriatric population. As people age, the likelihood of developing conditions that affect hemostasis, such as venous thromboembolism, atrial fibrillation, and other cardiovascular diseases, increases. Older individuals are als%li%more likely t%li%underg%li%surgeries that require accurate monitoring of coagulation levels t%li%avoid complications like excessive bleeding or clot formation. This demographic trend is boosting the demand for diagnostic tools that can assess blood clotting and bleeding risks.

Technological advancements in terms of product development are als%li%contributing t%li%market growth. The development of sophisticated and accurate diagnostic analyzers, such as point-of-care devices, has made it easier for healthcare providers

+357 96 030922
info@marketpublishers.com

t%li%quickly monitor coagulation parameters across various healthcare settings. These advancements have improved the speed and efficiency of diagnosing hemostasis disorders, which is particularly important in emergency and critical care settings.

In addition, innovations in testing platforms, such as automated analyzers and molecular diagnostic tests, have expanded the range of tests available, allowing for more precise detection of underlying causes of bleeding and clotting disorders.

Increased awareness and better understanding of bleeding disorders owing t%li%continuous research in emerging economies are driving the growth of the hemostasis diagnostics market. Public health campaigns and medical research have highlighted the importance of early diagnosis and intervention in managing conditions such as hemophilia, deep vein thrombosis (DVT), and pulmonary embolism. As a result, there is a greater emphasis on regular screening and monitoring of patients at risk of these conditions, which increases the demand for hemostasis diagnostic tests.

The rising prevalence of chronic diseases, particularly those related t%li%the cardiovascular system, is als%li%contributing t%li%the growth of the market. Cardiovascular diseases often lead t%li%clotting disorders, either due t%li%the formation of blood clots in the arteries or the use of anticoagulant therapies t%li%prevent strokes and heart attacks. As more individuals are diagnosed with chronic cardiovascular conditions, there is an increased need for diagnostic tests that can monitor blood clotting and bleeding risks, further driving the market.

Furthermore, the growing adoption of personalized medicine is playing a role in the hemostasis diagnostics market. In the context of hemostasis, personalized medicine can help identify patients wh%li%are at higher risk of bleeding or clotting disorders, enabling healthcare providers t%li%choose the most appropriate diagnostic tests and treatments. This trend is encouraging the development of more targeted diagnostic tools that can cater t%li%the specific needs of individual patients.

Some key players in the market are F. Hoffmann-La Roche AG; Danaher Corporation; Sysmex Corporation; Siemens Healthineers; Horiba Medical; Haemonetics Corporation; HemoSonics, LLC; Sterile Safequip and Chemicals LLP; TECO Medical Instruments; Stag%li%and more. Key strategies opted by the companies include innovation in product development, such as introducing more advanced, automated, and point-of-care diagnostic devices that offer faster, more accurate results. Strategic partnerships and collaborations with hospitals, research institutions, and other healthcare providers

+357 96 030922
info@marketpublishers.com

are als%li%crucial for expanding market reach and enhancing product offerings. Additionally, companies are focusing on expanding their product portfolios t%li%include a broader range of diagnostic tests, catering t%li%both routine and specialized testing needs.

Hemostasis Diagnostics Market Report Highlights

Based on product, consumables accounted for the largest revenue share of 61.1% in 2024. With the increasing number of tests being performed, the demand for consumables is likely t%li%show lucrative growth over the forecast period.

Based on test, the prothrombin time test dominated the market and accounted for the largest share of 31.5% in 2024.The PT test can be performed in various healthcare settings, including hospitals, clinics, and even point-of-care locations, making it accessible for timely diagnosis and treatment. Additionally, the test has a relatively short turnaround time, allowing clinicians t%li%make rapid decisions regarding patient care.

Based on end use, the hospitals segment dominated the market with the largest revenue share of 57.7% in 2024. The segment dominance is attributed t%li%large patient volumes being tested in hospitals.

North America dominated the global market owing t%li%well-established healthcare infrastructure allowing timely diagnosis and management of patients with bleeding and clotting disorders.

The Asia Pacific region is expected t%li%witness the fastest growth with a CAGR of 5.1% over the forecast period from 2025 t%li%2030, due t%li%the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is als%li%supporting the market growth.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

1.1. Market Segmentation & Scope
1.2. Segment Definitions
  1.2.1. Product
  1.2.2. Test
  1.2.3. End Use
  1.2.4. Regional scope
  1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
  1.4.1. Purchased database
  1.4.2. GVR's internal database
  1.4.3. Secondary sources
  1.4.4. Primary research
  1.4.5. Details of primary research
    1.4.5.1. Data for primary interviews in North America
    1.4.5.2. Data for primary interviews in Europe
    1.4.5.3. Data for primary interviews in Asia Pacific
    1.4.5.4. Data for primary interviews in Latin America
    1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
  1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
  1.7.1. Commodity flow analysis (Model 1)
  1.7.2. Approach 1: Commodity flow approach
  1.7.3. Volume price analysis (Model 2)
  1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Outlook
2.2. Segment Outlook

+357 96 030922
info@marketpublishers.com

2.2.1. Test outlook
2.2.2. Product outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights

CHAPTER 3. HEMOSTASIS DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Prevalence of Bleeding Disorders
3.2.1.2. Technological Advancements
3.2.1.3. Awareness of Preventive Healthcare
3.2.2. Market restraint analysis
3.2.2.1. High Cost of Advanced Devices
3.2.2.2. Lack of Skilled Personnel
3.3. Hemostasis Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape

CHAPTER 4. HEMOSTASIS DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

4.1. Product Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Hemostasis Diagnostics Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

+357 96 030922
info@marketpublishers.com

4.4.1. Laboratory Analyzers
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Automated Systems
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Semi-automated Systems
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Manual Systems
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Point-of-Care Testing Systems
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Consumables
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. HEMOSTASIS DIAGNOSTICS MARKET: TEST ESTIMATES & TREND ANALYSIS

5.1. Test Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Hemostasis Diagnostics Market by Test Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Activated Partial Thromboplastin Time
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. D-Dimer Test
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Fibrinogen Test
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Prothrombin Time (PT) Test
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Other Tests
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. HEMOSTASIS DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS

6.1. End Use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Hemostasis Diagnostics Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals

+357 96 030922
info@marketpublishers.com

6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Diagnostic Laboratories
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. HEMOSTASIS DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Target disease prevalence
7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Target disease prevalence
7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. Target disease prevalence
7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Target disease prevalence
7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)

+357 96 030922
info@marketpublishers.com

7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Target disease prevalence
7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Target disease prevalence
7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Target disease prevalence
7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Target disease prevalence
7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Target disease prevalence
7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Target disease prevalence
7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure

+357 96 030922
info@marketpublishers.com

7.6.8.3. Competitive scenario
7.6.8.4. Target disease prevalence
7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Target disease prevalence
7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Target disease prevalence
7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. Target disease prevalence
7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Target disease prevalence
7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. Target disease prevalence
7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Target disease prevalence

+357 96 030922
info@marketpublishers.com

7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Target disease prevalence
7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Argentina
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Target disease prevalence
7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. Target disease prevalence
7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Target disease prevalence
7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. Target disease prevalence
7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Target disease prevalence
7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

+357 96 030922
info@marketpublishers.com

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company market share analysis, 2024
8.3.2. F. Hoffmann-La Roche AG
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Danaher Corporation
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Sysmex Corporation
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Siemens Healthineers
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Horiba Medical
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Haemonetics Corporation
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. HemoSonics, LLC
8.3.8.1. Company overview

+357 96 030922
info@marketpublishers.com

8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Sterile Safequip and Chemicals LLP
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. TECO Medical Instruments
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Stago
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Hemostasis Diagnostics Market Size, Share & Trends Analysis Report By Product (POC Testing Systems, Consumables), By Test (Prothrombin Time Test, D Dimer Test), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/H0E11B791F7EEN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/H0E11B791F7EEN.html